PSYCHEMEDICS CORP - Quarter Report: 2005 September (Form 10-Q)
Table of Contents
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
| þ | QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For quarterly period ended September 30, 2005
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ________________ to ________________
Commission file number 1-13738
PSYCHEMEDICS CORPORATION
(exact name of Issuer as specified in its charter)
| Delaware | 58-1701987 | |
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation of organization) | Identification No.) |
| 125 Nagog Park, Acton, MA | 01720 | |
| (Address of principal executive offices) | (Zip Code) |
Issuer’s telephone number, including area code (978) 206-8220
Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15 (d) of the
Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Yes
þ No o
Indicate by check mark whether the registrant is an accelerated filer.
YES o NO þ
Indicate by check mark whether the registrant is a shell company.
YES o NO þ
Number of shares outstanding of only class of Issuer’s Common Stock as of
November 14, 2005: Common Stock $.005 par value (5,167,097 shares).
1
PSYCHEMEDICS CORPORATION
| Page No. | ||||||||
Part I FINANCIAL INFORMATION |
||||||||
Item 1 Financial Statements (Unaudited) |
||||||||
| 3 | ||||||||
| 4 | ||||||||
| 5 | ||||||||
| 6 | ||||||||
| 7-10 | ||||||||
| 11-16 | ||||||||
| 17 | ||||||||
| 17 | ||||||||
| 18 | ||||||||
| 18 | ||||||||
| 19 | ||||||||
| EX-31.1 SECTION 302 CERTIFICATION OF C.E.O. | ||||||||
| EX-31.2 SECTION 302 CERTIFICATION OF C.F.O. | ||||||||
| EX-32.1 SECTION 906 CERTIFICATION OF C.E.O. | ||||||||
| EX-32.2 SECTION 906 CERTIFICATION OF C.F.O. | ||||||||
2
Table of Contents
PSYCHEMEDICS CORPORATION
CONDENSED BALANCE SHEETS
| SEPTEMBER 30, | DECEMBER 31, | |||||||
| 2005 | 2004 | |||||||
| (Unaudited) | ||||||||
ASSETS |
||||||||
CURRENT ASSETS: |
||||||||
Cash and cash equivalents |
$ | 3,201,837 | $ | 3,260,178 | ||||
Short-term investments |
2,000,000 | — | ||||||
Accounts receivable, net of allowance for doubtful
accounts of $464,058 in 2005 and $483,230 in 2004 |
3,601,562 | 3,289,863 | ||||||
Prepaid expenses and other current assets |
431,902 | 246,372 | ||||||
Deferred tax assets |
529,752 | 529,752 | ||||||
Total current assets |
9,765,053 | 7,326,165 | ||||||
PROPERTY AND EQUIPMENT: |
||||||||
Equipment and leasehold improvements, at cost |
9,994,041 | 9,960,831 | ||||||
Less-accumulated depreciation and amortization |
(9,251,847 | ) | (9,099,472 | ) | ||||
| 742,194 | 861,359 | |||||||
DEFERRED TAX ASSETS |
166,583 | 166,583 | ||||||
OTHER ASSETS, NET |
39,829 | 79,529 | ||||||
| $ | 10,713,659 | $ | 8,433,636 | |||||
LIABILITIES AND SHAREHOLDERS’ EQUITY |
||||||||
CURRENT LIABILITIES: |
||||||||
Accounts payable |
$ | 401,655 | $ | 554,214 | ||||
Accrued expenses |
1,236,196 | 1,157,740 | ||||||
Deferred revenue |
581,440 | 487,633 | ||||||
Total current liabilities |
2,219,291 | 2,199,587 | ||||||
SHAREHOLDERS’ EQUITY: |
||||||||
Preferred stock, $0.005 par value; 872,521
shares authorized; none issued or outstanding |
— | — | ||||||
Common stock; $0.005 par value; 50,000,000
shares authorized; 5,750,894 shares and 5,710,704 shares
issued in 2005 and 2004, respectively |
28,754 | 28,554 | ||||||
Paid-in capital |
25,446,781 | 24,978,039 | ||||||
Accumulated deficit |
(7,858,476 | ) | (9,649,853 | ) | ||||
Less — Treasury stock, at cost; 583,797 shares |
(9,122,691 | ) | (9,122,691 | ) | ||||
Total shareholders’ equity |
8,494,368 | 6,234,049 | ||||||
| $ | 10,713,659 | $ | 8,433,636 | |||||
See accompanying notes to financial statements and management’s discussion and
analysis of financial condition and results of operations.
analysis of financial condition and results of operations.
3
Table of Contents
PSYCHEMEDICS CORPORATION
CONDENSED STATEMENTS OF INCOME
(UNAUDITED)
| THREE MONTHS | ||||||||
| ENDED SEPTEMBER 30, | ||||||||
| 2005 | 2004 | |||||||
REVENUE |
$ | 5,353,168 | $ | 4,870,218 | ||||
COST OF REVENUE |
2,267,237 | 2,105,768 | ||||||
Gross profit |
3,085,931 | 2,764,450 | ||||||
EXPENSES: |
||||||||
General and administrative |
765,758 | 803,940 | ||||||
Marketing and selling |
703,731 | 673,724 | ||||||
Research and development |
87,090 | 83,854 | ||||||
| 1,556,579 | 1,561,518 | |||||||
OPERATING INCOME |
1,529,352 | 1,202,932 | ||||||
INTEREST INCOME |
34,269 | 8,476 | ||||||
OTHER INCOME |
— | 3,750 | ||||||
| 34,269 | 12,226 | |||||||
NET INCOME BEFORE INCOME TAXES |
1,563,621 | 1,215,158 | ||||||
PROVISION FOR INCOME TAXES |
581,000 | 414,000 | ||||||
NET INCOME |
$ | 982,621 | $ | 801,158 | ||||
BASIC NET INCOME PER SHARE |
$ | 0.19 | $ | 0.16 | ||||
DILUTED NET INCOME PER SHARE |
$ | 0.19 | $ | 0.16 | ||||
DIVIDENDS DECLARED PER SHARE |
$ | 0.10 | $ | 0.08 | ||||
WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING, BASIC |
5,167,097 | 5,126,907 | ||||||
WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING, DILUTED |
5,179,134 | 5,132,976 | ||||||
See accompanying notes to financial statements and management’s discussion and
analysis of financial condition and results of operations.
analysis of financial condition and results of operations.
4
Table of Contents
PSYCHEMEDICS CORPORATION
CONDENSED STATEMENTS OF INCOME
(UNAUDITED)
| NINE MONTHS | ||||||||
| ENDED SEPTEMBER 30, | ||||||||
| 2005 | 2004 | |||||||
REVENUE |
$ | 16,306,247 | $ | 14,373,139 | ||||
COST OF REVENUE |
6,656,516 | 6,362,714 | ||||||
Gross profit |
9,649,731 | 8,010,425 | ||||||
EXPENSES: |
||||||||
General and administrative |
2,394,370 | 2,416,796 | ||||||
Marketing and selling |
2,110,980 | 1,893,877 | ||||||
Research and development |
232,891 | 234,192 | ||||||
| 4,738,241 | 4,544,865 | |||||||
OPERATING INCOME |
4,911,490 | 3,465,560 | ||||||
INTEREST INCOME |
73,867 | 23,376 | ||||||
OTHER INCOME |
1,250 | 11,250 | ||||||
| 75,117 | 34,626 | |||||||
NET INCOME BEFORE INCOME TAXES |
4,986,607 | 3,500,186 | ||||||
PROVISION FOR INCOME TAXES |
1,855,000 | 1,282,000 | ||||||
NET INCOME |
$ | 3,131,607 | $ | 2,218,186 | ||||
BASIC NET INCOME PER SHARE |
$ | 0.61 | $ | 0.43 | ||||
DILUTED NET INCOME PER SHARE |
$ | 0.61 | $ | 0.43 | ||||
DIVIDENDS DECLARED PER SHARE |
$ | 0.26 | $ | 0.24 | ||||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING, BASIC |
5,153,178 | 5,126,907 | ||||||
WEIGHTED
AVERAGE COMMON SHARES OUTSTANDING, DILUTED |
5,165,060 | 5,131,946 | ||||||
See accompanying notes to financial statements and management’s discussion and
analysis of financial condition and results of operations.
analysis of financial condition and results of operations.
5
Table of Contents
PSYCHEMEDICS CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| NINE MONTHS | ||||||||
| ENDED SEPTEMBER 30, | ||||||||
| 2005 | 2004 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||
Net income |
$ | 3,131,607 | $ | 2,218,186 | ||||
Adjustments to reconcile net income to net
cash provided by operating activities: |
||||||||
Depreciation and amortization |
318,073 | 404,491 | ||||||
Tax benefit associated with exercise of options |
35,503 | — | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(311,699 | ) | (885,642 | ) | ||||
Prepaid expenses and other assets |
(185,530 | ) | (52,955 | ) | ||||
Accounts payable |
(152,559 | ) | 106,119 | |||||
Accrued expenses |
78,456 | 315,474 | ||||||
Deferred revenue |
93,807 | 36,356 | ||||||
Net cash provided by operating activities |
3,007,658 | 2,142,029 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||
Purchases of short-term investments |
(2,000,000 | ) | — | |||||
Purchases of property and equipment |
(163,507 | ) | (251,674 | ) | ||||
Decrease (Increase) in other assets — net |
4,299 | (6,180 | ) | |||||
Net cash used in investing activities |
(2,159,208 | ) | (257,854 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||
Cash dividends paid |
(1,340,230 | ) | (1,230,458 | ) | ||||
Net proceeds from the issuance of common stock |
433,439 | — | ||||||
Net cash used in financing activities |
(906,791 | ) | (1,230,458 | ) | ||||
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
(58,341 | ) | 653,717 | |||||
CASH AND CASH EQUIVALENTS, beginning of period |
3,260,178 | 3,022,467 | ||||||
CASH AND CASH EQUIVALENTS, end of period |
$ | 3,201,837 | $ | 3,676,184 | ||||
See accompanying notes to financial statements and management’s discussion and
analysis of financial condition and results of operations.
analysis of financial condition and results of operations.
6
Table of Contents
PSYCHEMEDICS CORPORATION
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
September 30, 2005
1. Interim Financial Statements
The accompanying unaudited interim financial statements have been prepared in accordance with
generally accepted accounting principles for interim financial information and pursuant to the
rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q.
Accordingly, certain information and footnote disclosure required for complete financial statements
are not included herein. It is recommended that these financial statements be read in conjunction
with the financial statements and related notes of Psychemedics Corporation (the “Company”) as
reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2004. In the
opinion of management, all adjustments (consisting of normal recurring adjustments) considered
necessary for a fair presentation of financial position, results of operations, and cash flows at
the dates and for the periods presented have been included. The results of operations for the
three months and the nine months ended September 30, 2005 may not be indicative of the results that
may be expected for the year ending December 31, 2005, or any other period.
2. Stock-Based Compensation
The Company accounts for its stock compensation arrangements with employees under the provisions of
Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees. The
Company has adopted the disclosure-only provisions of SFAS No. 123, Accounting for Stock-Based
Compensation, as amended by SFAS No. 148, Accounting for Stock-Based Compensation – Transition and
Disclosure.
Statement of Financial Accounting Standards, (SFAS) No. 123, Accounting for Stock-Based
Compensation, requires the measurement of the fair value of stock options or warrants to be
included in the statement of income or disclosed in the notes to financial statements. The Company
has computed the value of options using the Black-Scholes option pricing model prescribed by SFAS
No. 123.
The assumptions used and the weighted average information are as follows:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, 2005 | September 30, 2004 | September 30, 2005 | September 30, 2004 | |||||||||||||
Risk-free interest rates range |
— | — | 3.8 | % | 2.7 – 3.9 | % | ||||||||||
Expected dividend yield range |
— | — | 2.3 | % | 2.7 | % | ||||||||||
Expected lives |
— | — | 5 years | 5 years | ||||||||||||
Expected volatility range |
— | — | 30.09 | % | 23.99 – 27.94 | % | ||||||||||
7
Table of Contents
PSYCHEMEDICS CORPORATION
NOTES TO CONDENSED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONDENSED FINANCIAL STATEMENTS — (Continued)
Consistent with SFAS No. 123, net income and basic and diluted net income per share would have been
as follows:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, 2005 | September 30, 2004 | September 30, 2005 | September 30, 2004 | |||||||||||||
Net income, as reported |
$ | 982,621 | $ | 801,158 | $ | 3,131,607 | $ | 2,218,186 | ||||||||
Less: Total stock
based compensation
cost determined under
the fair value based
method for all
employee awards |
(9,558 | ) | (25,371 | ) | (938,440 | ) | (133,307 | ) | ||||||||
Pro forma net income |
$ | 973,063 | $ | 775,787 | $ | 2,193,167 | $ | 2,084,879 | ||||||||
Income per share: |
||||||||||||||||
Basic, as reported |
$ | 0.19 | $ | 0.16 | $ | 0.61 | $ | 0.43 | ||||||||
Diluted, as reported |
$ | 0.19 | $ | 0.16 | $ | 0.61 | $ | 0.43 | ||||||||
Basic, pro forma |
$ | 0.19 | $ | 0.15 | $ | 0.43 | $ | 0.41 | ||||||||
Diluted, pro forma |
$ | 0.19 | $ | 0.15 | $ | 0.42 | $ | 0.41 | ||||||||
No options were granted for the three months ended September 30, 2005 or 2004. The fair value of
options granted for the nine months ended September 30, 2005 and 2004 was $3.76 per share and $2.19
per share, respectively.
3. Basic and Diluted Net Income Per Share
Basic net income per share was computed by dividing net income by the weighted average number of
common shares outstanding during the period. Diluted net income per share was computed by dividing
net income by the weighted average number of common and dilutive common equivalent shares
outstanding during the period. The number of dilutive common equivalent shares outstanding during
the period has been determined in accordance with the treasury-stock method. Common equivalent
shares consist of common stock issuable upon the exercise of outstanding options.
Basic and diluted weighted average common shares outstanding were as follows:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, 2005 | September 30, 2004 | September 30, 2005 | September 30, 2004 | |||||||||||||
Weighted average common shares |
5,167,097 | 5,126,907 | 5,153,178 | 5,126,907 | ||||||||||||
Dilutive common stock options |
12,037 | 6,069 | 11,882 | 5,039 | ||||||||||||
Weighted average common shares outstanding, assuming dilution |
5,179,134 | 5,132,976 | 5,165,060 | 5,131,946 | ||||||||||||
8
Table of Contents
PSYCHEMEDICS CORPORATION
NOTES TO CONDENSED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONDENSED FINANCIAL STATEMENTS — (Continued)
For the three months ended September 30, 2005 and 2004, options to purchase 449,207 and 368,912
common shares, respectively, were outstanding but not included in the diluted weighted average
common share calculation as the effect would have been antidilutive. For the nine months ended
September 30, 2005 and 2004, options to purchase 484,208 and 384,362 common shares, respectively,
were outstanding but not included in the diluted weighted average common share calculation as the
effect would have been antidilutive.
4. Revenue Recognition
The Company performs drug testing as well as provides training for collection of samples and
storage of positive samples for its customers for an agreed-upon fee per unit tested of samples.
Revenues are recognized when the predominant deliverable, drug testing, is provided and reported to
the customer. The Company also provides expert testimony, when and if necessary, to support the
results of the tests, which is generally billed separately and recognized as the services are
provided.
In 2003, the Company adopted Emerging Issue Task Force 00-21, Revenue Arrangements with Multiple
Deliverables, which was effective for all transactions entered into subsequent to June 15, 2003.
The Company applied the consensus reached under EITF 00-21 and concluded that the testing, training
and storage elements are considered one unit of accounting for revenue recognition purposes as the
training and storage costs do not have stand-alone value to the customer. The Company has concluded
that the predominant deliverable in the arrangement is the testing of the units and has recognized
revenue as that service is performed and reported to the customer.
At September 30, 2005 and December 31, 2004, the Company had deferred revenue of approximately
$581,000 and $488,000, respectively, reflecting sales of its personal drug testing service for
which the performance of the related test had not yet occurred.
5. Recent Accounting Pronouncements
In December 2004, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 123 (revised
2004), Share-Based Payment, which is a revision of SFAS No. 123, Accounting for Stock-Based
Compensation. SFAS No. 123(R) supersedes APB Opinion No. 25, Accounting for Stock Issued to
Employees, and amends SFAS No. 95, Statement of Cash Flows. Generally, the approach in SFAS No.
123(R) is similar to the approach described in SFAS No. 123. However, SFAS No. 123(R) requires all
share-based payments to employees, including grants of employee stock options, to be recognized in
the income statement based on their fair values. Pro forma disclosure is no longer an alternative.
The provisions of SFAS No. 123(R) are effective for all employee equity awards granted and to any
unvested awards outstanding as of January 1, 2006. The Company currently does not expect the
impact of adopting this new standard to be of a material nature.
9
Table of Contents
PSYCHEMEDICS CORPORATION
NOTES TO CONDENSED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONDENSED FINANCIAL STATEMENTS — (Continued)
6. Contingencies
The Company is subject to legal proceedings and claims, which arise in the ordinary course of its
business. The Company believes that based upon information available to the Company at this time,
the expected outcome of these matters would not have a material impact on the Company’s results of
operations or financial condition.
7. Subsequent Event — Dividends
On October 26, 2005, the Company declared a quarterly dividend of $.10 per share, which will be
paid on December 23, 2005 to shareholders of record on December 9, 2005.
10
Table of Contents
Item 2
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
Psychemedics Corporation was incorporated in 1986. The Company utilizes a patented hair analysis
method involving radioimmunoassay technology to analyze human hair to detect abused substances.
Revenue for the third quarter of 2005 was $5.4 million and was 10% above revenue of $4.9 million
for the third quarter of 2004. Revenue for the first three quarters of 2005 was $16.3 million and
was 13% above revenue of $14.4 million for the first three quarters of 2004. Due to the increase
in revenue and gross profit, the Company reported net income of $0.19 per share in the quarter
ended September 30, 2005 and net income of $0.61 per share for the nine months ended September 30,
2005. At September 30, 2005, the Company had $5.2 million of cash, cash equivalents and short-term
investments. The Company distributed $0.5 million, or $0.10 per share, of cash dividends to its
shareholders in the third quarter of 2005, and $0.4 million, or $0.08 per share, of cash dividends
in both the first and second quarters of 2005, which represented year to date totals of $1.3
million, or $0.26 per share. As of the date of this Report, the Company has paid thirty-six
consecutive quarterly cash dividends.
RESULTS OF OPERATIONS
Revenue was $5,353,168 for the three month period ended September 30, 2005 as compared to
$4,870,218 for the comparable period of 2004, representing an increase of 10%. Revenue was
$16,306,247 for the nine month period ended September 30, 2005 as compared to $14,373,139 for the
comparable period of 2004, representing an increase of 13%. The increase in revenue for the third
quarter of 2005 was due to an increase of 11% in testing volume from both new and existing clients,
while the average revenue per sample decreased by approximately 1% as compared to the comparable
period of 2004. The increase in revenue for the nine months ended September 30, 2005 was due to an
increase of 14% in testing volume from both new and existing clients, while the average revenue per
sample decreased by 1% as compared to the comparable period of 2004. The Company believes that the
growth in testing volume was due to an improvement in the hiring environment at new and existing
customers. The Company continued to add approximately the same number of new clients for the nine
months ended September 30, 2005 as it did in the comparable period of 2004.
Gross margin was 58% of revenue for the three month period ended September 30, 2005, as compared to
57% for the comparable period of 2004. Gross margin was 59% of revenue for the nine month period
ended September 30, 2005, as compared to 56% for the comparable period of 2004. Fixed and
semi-variable direct costs were spread over a greater number of tests performed for the three month
period and the nine month period ended September 30, 2005, as compared to the same periods of 2004.
Also, reduced depreciation and amortization expense contributed to a decline in fixed costs for
the three month period and the nine month period ended September 30, 2005 as compared to the year
earlier periods.
11
Table of Contents
General and administrative (“G&A”) expenses were $765,758 for the three month period ended
September 30, 2005 as compared to $803,940 for the comparable period of 2004, representing a
decrease of 5%. G&A expenses were $2,394,370 for the nine month period ended September 30, 2005 as
compared to $2,416,796 for the comparable period of 2004, representing a decrease of 1%. The
decrease in general and administrative expenses for the three month period ended September 30, 2005
as compared to the comparable period of 2004 was due primarily to reduced professional fees related
to legal services and a decrease in rent expense pertaining to the Company’s headquarters,
partially offset by greater professional fees related to Sarbanes-Oxley compliance. All other
general and administrative expenses remained relatively constant. The decrease in general and
administrative expenses for the nine month period ended September 30, 2005 as compared to the
comparable period of 2004 was due primarily to reduced professional fees related to legal services
and a decrease in rent expense pertaining to the Company’s headquarters, partially offset by
greater professional fees related to Sarbanes-Oxley compliance along with an increase in personnel
expenses. All other general and administrative expenses remained relatively constant. As a
percentage of revenue, G&A expenses decreased to 14% for the three month period ended September 30,
2005 from 17% for the comparable period of 2004 and decreased to 15% for the nine months ended
September 30, 2005 from 17% for the comparable period of 2004. The Company expects general and
administrative expenses to remain relatively flat during the remainder of 2005.
Marketing and selling expenses were $703,731 for the three month period ended September 30, 2005 as
compared to $673,724 for the comparable period of 2004, an increase of 4%. Marketing and selling
expenses were $2,110,980 for the nine month period ended September 30, 2005 as compared to
$1,893,877 for the comparable period of 2004, an increase of 11%. The increase for both the three
month and the nine month periods ended September 30, 2005 as compared to the comparable periods of
2004 was due primarily to an increase in personnel expenses pertaining to the Company’s sales and
support staff. Total marketing and selling expenses represented 13% of revenue in the third
quarter of 2005 and 14% of revenue in the third quarter of 2004. Total marketing and selling
expenses represented 13% of revenue for the nine month period ended September 30, 2005 and 13% of
revenue for the nine month period ended September 30, 2004. Even though the Company does not
anticipate any significant increases in marketing and selling expenses during the remainder of
2005, the Company does expect to continue to aggressively promote its drug testing services in
future years in order to expand its client base.
Research and development (“R&D”) expenses for the three month period ended September 30, 2005
increased by $3,236 from the comparable period of the prior year to $87,090, an increase of 4%.
This increase was primarily due to increased personnel and consulting costs, partially offset by
reduced consumables costs. Research and development (“R&D”) expenses for the nine month period
ended September 30, 2005 decreased by $1,301 from the comparable period of the prior year to
$232,891, a decrease of 1%. This decrease was primarily due to reduced consumables costs. R&D
expenses represented 2% of revenue for both of the three month periods ended September 30, 2005 and
September 30, 2004. R&D expenses represented 1% of revenue for the nine month period ended
September 30, 2005 and 2% of revenue for the nine month period ended September 30, 2004. The
Company does not expect any significant changes in research and development expenses during the
remainder of 2005.
12
Table of Contents
Interest income for the three month period ended September 30, 2005 increased by $25,793 and
increased by $50,491 for the nine month period ended September 30, 2005 as compared to the
comparable year periods and represented interest earned on cash equivalents and short-term
investments. Higher average investment balances along with an increase in the yield on investment
balances in 2005 as compared to 2004 caused the increase in interest income.
During the three month period ended September 30, 2005, the Company recorded a tax provision of
$581,000 reflecting an effective tax rate of 37.2% as compared to a tax provision of $414,000
reflecting an effective tax rate of 34.1% for the three month period ended September 30, 2004.
During the nine months ended September 30, 2005 and September 30, 2004, the Company recorded tax
provisions of $1,855,000 and $1,282,000 representing effective tax rates of 37.2% and 36.6%,
respectively. The variation in the effective tax rate resulted from the Company reducing its tax
accrual and tax provision by $40,000 during the third quarter of 2004 in order to properly reflect
its estimated taxes payable.
LIQUIDITY AND CAPITAL RESOURCES
At September 30, 2005, the Company had approximately $5.2 million of cash, cash equivalents and
short-term investments. The Company’s operating activities generated net cash of $3,007,658 in the
nine months ended September 30, 2005. Investing activities used $2,159,208 in the nine month
period while financing activities used a net amount of $906,791 during the period.
Operating cash flow of $3,007,658 for the nine months ended September 30, 2005 principally
reflected net income of $3,131,607 adjusted for depreciation and amortization of $318,073 offset
partially by the growth in accounts receivable and prepaid expenses along with the decrease in
accounts payable.
Capital expenditures in the first three quarters of 2005 were $163,507. The expenditures primarily
consisted of new equipment, including laboratory and computer equipment. The Company currently
plans to make additional capital expenditures of approximately $200,000 during the balance of 2005,
primarily in connection with the purchase of additional laboratory and computer equipment. The
Company believes that within the next two to five years it may be required to expand its existing
laboratory or develop a second laboratory, the cost of which is currently believed to range from $2
million to $4 million.
During the nine month period ended September 30, 2005, the Company distributed $1,340,230 in cash
dividends to its shareholders. The Company did not repurchase any shares for treasury during the
nine month period ended September 30, 2005. The Company has authorized 500,000 shares for
repurchase since June of 1998 of which 466,351 shares have been repurchased as of September 30,
2005.
13
Table of Contents
Contractual obligations as of September 30, 2005 were as follows:
| Less Than | 1-3 | 4-5 | After 5 | |||||||||||||||||
| One Year | Years | Years | Years | Total | ||||||||||||||||
Operating leases |
$ | 487,000 | $ | 909,000 | $ | 885,000 | $ | 681,000 | $ | 2,962,000 | ||||||||||
Purchase commitment |
247,000 | — | — | — | 247,000 | |||||||||||||||
| $ | 734,000 | $ | 909,000 | $ | 885,000 | $ | 681,000 | $ | 3,209,000 | |||||||||||
The Company signed a seven year extension in May of 2005 with an option to renew for an additional
three years on the space leased for laboratory purposes in Culver City, California. This extension
commences on January 1, 2006. The Company also signed a five year lease extension in May of 2005
with an option to renew for an additional two years on the space leased for customer service and
information technology purposes in Culver City, California. This extension also commences on
January 1, 2006. The lease obligations are reflected in the above table.
Purchase Commitment
The Company has a supply agreement with a vendor which requires the Company to purchase isotopes
used in its drug testing procedures from this sole supplier in exchange for variable annual
payments based upon prior year purchases. Purchases amounted to $370,727 for the nine months ended
September 30, 2005 as compared to $329,301 for the comparable period of 2004. The Company expects
to purchase approximately $124,000 for the remainder of 2005. In exchange for exclusivity, the
supplier has provided the Company with the right to purchase the isotope technology at fair market
value under certain conditions, including the failure to meet the Company’s purchase commitments.
This agreement does not include a fixed termination date; however, it is cancelable upon mutual
agreement by both parties or six months after termination notice by the Company of its intent to
use a different technology in connection with its drug testing procedures.
At September 30, 2005, the Company’s principal sources of liquidity included an aggregate of
approximately $5.2 million of cash, cash equivalents and short-term investments. Management
currently believes that such funds, together with cash generated from operations, should be
adequate to fund anticipated working capital requirements and capital expenditures in the near
term. Depending upon the Company’s results of operations, its future capital needs and available
marketing opportunities, the Company may use various financing sources to raise additional funds.
Such sources could potentially include joint ventures, issuances of common stock or debt financing,
although the Company does not have any such plans at this time. At September 30, 2005, the Company
had no long-term debt.
14
Table of Contents
CRITICAL ACCOUNTING POLICIES
Management believes the most critical accounting policies include revenue recognition and income
taxes.
Revenue Recognition
The Company is in the business of performing drug testing and reporting the results thereof. The
Company performs drug testing which includes training for collection of samples and storage of
positive samples for its customers for an agreed-upon fee per unit tested of samples. The revenues
are recognized when the predominant deliverable, drug testing, is provided and reported to the
customer. The Company also provides expert testimony, when and if necessary, to support the test
results, which is generally billed separately and recognized as the services are provided.
In 2003, the Company adopted Emerging Issue Task Force 00-21, Revenue Arrangements with Multiple
Deliverables, which was effective for all transactions entered into subsequent to June 15, 2003.
The Company applied the consensus reached under EITF 00-21 and concluded that the testing, training
and storage elements are considered one unit of accounting for revenue recognition purposes as the
training and storage costs do not have stand-alone value to the customer. The Company has concluded
that the predominant deliverable in the arrangement is the testing of the units and has recognized
revenue as that service is performed and reported to the customer.
Deferred revenue represents payments received in advance of the performance of drug testing
procedures. Deferred revenue is reclassified as revenue when the underlying test results are
delivered. With respect to a portion of these transactions, there may be instances where the
customer ultimately does not require performance (referred to as breakage). Revenue is then
recognized (as other income) when the Company can reasonably, reliably and objectively determine
the breakage has occurred. Breakage is deemed to occur only at the point it becomes remote that
performance will be required. The Company has not recorded any breakage in the first three
quarters of 2005 and during 2004. The Company continues to monitor this to determine whether
breakage can be reasonably, reliably and objectively determined.
Estimates
The preparation of financial statements in conformity with accounting principles generally accepted
in the United States requires management to make estimates, including bad debts and income taxes,
and assumptions that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Actual results could differ from those
estimates.
Allowance for Doubtful Accounts
The allowance for doubtful accounts is based on management’s assessment of the collectibility of
its customer accounts. Management reviews its accounts receivable aging for doubtful accounts and
specifically identifies accounts that may not be collectible. The Company routinely assesses the
financial strength of its customers
15
Table of Contents
and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The
Company maintains an allowance for potential credit losses but historically has not experienced any
significant losses related to individual customers or groups of customers in any particular
industry or geographic area. Bad debt expense and the issuance of credit memos have been within
management’s expectations.
Income Taxes
The Company accounts for income taxes using the liability method, which requires the Company to
recognize a current tax liability or asset for current taxes payable or refundable and a deferred
tax liability or asset for the estimated future tax effects of temporary differences between the
financial statement and tax reporting bases of assets and liabilities to the extent that they are
realizable. Deferred tax expense (benefit) results from the net change in deferred tax assets and
liabilities during the year. A deferred tax valuation allowance is required if it is more likely
than not that all or a portion of the recorded deferred tax assets will not be realized.
The Company operates within multiple taxing jurisdictions and could be subject to audit in these
jurisdictions. These audits may involve complex issues, which may require an extended period of
time to resolve. The Company has provided for its estimated taxes payable in the accompanying
financial statements.
The above listing is not intended to be a comprehensive list of all of the Company’s accounting
policies. In many cases, the accounting treatment of a particular transaction is specifically
dictated by accounting principles generally accepted in the United States, with no need for
management’s judgment in their application. There are also areas in which management’s judgment in
selecting any available alternative would not produce a materially different result.
FACTORS THAT MAY AFFECT FUTURE RESULTS
From time to time, information provided by the Company or statements made by its employees may
contain “forward-looking” information which involves risks and uncertainties. In particular,
statements contained in this report which are not historical facts (including, but not limited to,
the Company’s expectations regarding revenues, business strategy, anticipated operating results,
strategies with respect to governmental agencies and regulations, cash dividends, capital
expenditures and anticipated cash requirements) may be “forward-looking” statements. The Company’s
actual results may differ from those stated in any “forward-looking” statements. Factors that may
cause such differences include, but are not limited to, employee hiring practices of the Company’s
principal customers, development of markets for new products and services offered by the Company,
the economic health of principal customers of the Company, financial and operational risks
associated with possible expansion of testing facilities used by the Company, government regulation
(including, but not limited to, Food and Drug Administration regulations), competition and general
economic conditions. With respect to the continued payment of cash dividends, factors include, but
are not limited to, available surplus, cash flow, capital expenditure reserves required, and other
factors that the Board of Directors of the Company may take into account.
16
Table of Contents
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Interest Rate Sensitivity. The Company maintains a short-term investment portfolio consisting
principally of money market securities and Taxable Auction Rate Preferred, 7 and 28 day Dutch
Auction securities that are not sensitive to sudden interest rate changes. The Company does not
use derivative financial instruments for speculative or trading purposes.
Item 4. Controls and Procedures
As of September 30, 2005, our Chief Executive Officer and Chief Financial Officer performed an
evaluation of the effectiveness of the design and operation of the Company’s disclosure controls
and procedures pursuant to Exchange Act Rule 13a-14. Based upon that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and
procedures are effective in ensuring the reporting of material information required to be included
in the Company’s periodic filings with the Securities and Exchange Commission. There were no
significant changes in the Company’s internal controls over financial reporting or in other factors
that could significantly affect these internal controls over financial reporting subsequent to the
date of the most recent evaluation.
17
Table of Contents
PART II OTHER INFORMATION
Item 6. Exhibits
See Exhibit Index included in this Report
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Psychemedics Corporation |
||||
| Date: November 14, 2005 | By: | /s/ Raymond C. Kubacki, Jr. | ||
| Raymond C. Kubacki, Jr. | ||||
| Chairman and Chief Executive Officer | ||||
| Date: November 14, 2005 | By: | /s/ Peter C. Monson | ||
| Peter C. Monson | ||||
| Vice President, Treasurer & Chief Financial Officer | ||||
18
Table of Contents
PSYCHEMEDICS CORPORATION
FORM 10-Q
September 30, 2005
FORM 10-Q
September 30, 2005
EXHIBIT INDEX
| Page No. | ||||
31.1 |
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | 20 | ||
31.2 |
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | 22 | ||
32.1 |
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | 24 | ||
32.2 |
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | 25 |
19